Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q58404435)
Watch
English
New antifungal agents
scientific article published on 01 July 2003
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PubMed publication ID
12956208
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12956208%20AND%20SRC:MED&resulttype=core&format=json
retrieved
7 November 2019
review article
1 reference
stated in
Europe PubMed Central
title
New antifungal agents
(English)
1 reference
stated in
Europe PubMed Central
PubMed publication ID
12956208
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12956208%20AND%20SRC:MED&resulttype=core&format=json
retrieved
7 November 2019
author
Aditya K. Gupta
series ordinal
1
1 reference
stated in
Europe PubMed Central
PubMed publication ID
12956208
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12956208%20AND%20SRC:MED&resulttype=core&format=json
retrieved
7 November 2019
author name string
Elizabeth Tomas
series ordinal
2
1 reference
stated in
Europe PubMed Central
PubMed publication ID
12956208
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12956208%20AND%20SRC:MED&resulttype=core&format=json
retrieved
7 November 2019
publication date
1 July 2003
1 reference
stated in
Europe PubMed Central
PubMed publication ID
12956208
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12956208%20AND%20SRC:MED&resulttype=core&format=json
retrieved
7 November 2019
published in
Dermatologic Clinics
1 reference
stated in
Europe PubMed Central
PubMed publication ID
12956208
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12956208%20AND%20SRC:MED&resulttype=core&format=json
retrieved
7 November 2019
volume
21
1 reference
stated in
Europe PubMed Central
PubMed publication ID
12956208
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12956208%20AND%20SRC:MED&resulttype=core&format=json
retrieved
7 November 2019
issue
3
1 reference
stated in
Europe PubMed Central
PubMed publication ID
12956208
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12956208%20AND%20SRC:MED&resulttype=core&format=json
retrieved
7 November 2019
page(s)
565-576
1 reference
stated in
Europe PubMed Central
PubMed publication ID
12956208
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12956208%20AND%20SRC:MED&resulttype=core&format=json
retrieved
7 November 2019
cites work
New investigational antifungal agents for treating invasive fungal infections
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Uncommon opportunistic fungi: new nosocomial threats
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Changing spectrum of invasive candidiasis and its therapeutic implications
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The epidemiology of candidaemia and mould infections in Australia
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Present status of the detection of antifungal resistance: the perspective from both sides of the ocean
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Optimizing voriconazole susceptibility testing of Candida: effects of incubation time, endpoint rule, species of Candida, and level of fluconazole susceptibility
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Comparison of in vitro activities of voriconazole and five established antifungal agents against different species of dermatophytes using a broth macrodilution method
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: review of the literature
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Mortality and costs of acute renal failure associated with amphotericin B therapy
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Lipid-based antifungal agents: current status
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Lipid-based amphotericin B: a review of the last 10 years of use.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Amphotericin B lipid complex
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A comparative review of conventional and lipid formulations of amphotericin B.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Treatment of dermatomycoses and onychomycoses--state of the art
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Cryptococcosis in Australasia and the treatment of cryptococcal and other fungal infections with liposomal amphotericin B.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
AmBisome in the treatment of fungal infections: the UK experience
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Amphotericin B nephrotoxicity
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Overview of the lipid formulations of amphotericin B.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Liposomal amphotericin B (AmBisome): efficacy and safety of low-dose therapy in pulmonary fungal infections
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Ten years' experience with liposomal amphotericin B in transplant recipients at Huddinge University Hospital
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Liposomal amphotericin B (AmBisome) for fungal infections in immunocompromised adults and children
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Voriconazole: a new triazole antifungal
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
In vitro studies of two triazole antifungal agents (voriconazole [UK-109,496] and fluconazole) against Candida species
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Voriconazole (UK-109,496) inhibits the growth and alters the morphology of fluconazole-susceptible and -resistant Candida species
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
In vitro activity of voriconazole against Candida species
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Fluconazole and voriconazole multidisk testing of Candida species for disk test calibration and MIC estimation
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
In vitro activity of three new triazoles and one echinocandin against Candida bloodstream isolates from cancer patients
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
In vitro activities of voriconazole (UK-109,496) and four other antifungal agents against 394 clinical isolates of Candida spp
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Voriconazole against fluconazole-susceptible and resistant candida isolates: in-vitro efficacy compared with that of itraconazole and ketoconazole.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobia
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
In vitro susceptibilities of Candida dubliniensis isolates tested against the new triazole and echinocandin antifungal agents
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Anticryptococcal activity of voriconazole against Cryptococcus neoformans var. gatti vs var. neoformans: comparison with fluconazole and effect of human serum
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
In vitro activities of four novel triazoles against Scedosporium spp
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
In vitro antifungal susceptibilities of Trichosporon species.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance P
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Nationwide survey of in vitro activities of itraconazole and voriconazole against clinical Aspergillus fumigatus isolates cultured between 1945 and 1998.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
In-vitro activities of amphotericin B, itraconazole and voriconazole against 150 clinical and environmental Aspergillus fumigatus isolates.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
In vitro evaluation of voriconazole against clinical isolates of yeasts, moulds and dermatophytes in comparison with itraconazole, ketoconazole, amphotericin B and griseofulvin
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
In vitro activities of voriconazole, itraconazole, and amphotericin B against Blastomyces dermatitidis, Coccidioides immitis, and Histoplasma capsulatum
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
In vitro activities of 10 antifungal drugs against 508 dermatophyte strains
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Optimizing the correlation between results of testing in vitro and therapeutic outcome in vivo for fluconazole by testing critical isolates in a murine model of invasive candidiasis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Standardization of antifungal susceptibility variables for a semiautomated methodology
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Efficacy of voriconazole against invasive pulmonary aspergillosis in a guinea-pig model
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The exciting future of antifungal therapy
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Efficacy of voriconazole in a guinea pig model of disseminated invasive aspergillosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Antifungal activity of the new azole UK-109, 496 (voriconazole)
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Investigational antifungal agents.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
In vitro activity of the new triazole BMS-207147 against Aspergillus species in comparison with itraconazole and amphotericin B
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
In Vitro Activity of a New Oral Triazole, BMS-207147 (ER-30346).
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
In vitro and in vivo antifungal activities of ER-30346, a novel oral triazole with a broad antifungal spectrum
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
In vitro activities of ravuconazole (BMS-207147) against 541 clinical isolates of Cryptococcus neoformans
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Efficacy of ravuconazole in treatment of systemic murine histoplasmosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Efficacy of ER-30346, a novel oral triazole antifungal agent, in experimental models of aspergillosis, candidiasis, and cryptococcosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Effect of ravuconazole, a new triazole antifungal, in a rat intraabdominal abscess model
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Efficacies of two new antifungal agents, the triazole ravuconazole and the echinocandin LY-303366, in an experimental model of invasive aspergillosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Efficacy of ravuconazole in treatment of mucosal candidosis in SCID mice
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
In vitro activity of SCH-56592 and comparison with activities of amphotericin B and itraconazole against Aspergillus spp.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Activity of SCH 56592 compared with those of fluconazole and itraconazole against Candida spp
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Activity of a new triazole, Sch 56592, compared with those of four other antifungal agents tested against clinical isolates of Candida spp. and Saccharomyces cerevisiae
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
In vitro activity of posaconazole against clinical isolates of dermatophytes
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Comparison of a new triazole, posaconazole, with itraconazole and amphotericin B for treatment of histoplasmosis following pulmonary challenge in immunocompromised mice
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Comparative in vitro activity of voriconazole and itraconazole against fluconazole-susceptible and fluconazole-resistant clinical isolates of Candida species from Spain.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolates
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Azole cross-resistance in Aspergillus fumigatus
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Caspofungin
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Clinical efficacy of echinocandin antifungals
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
In vitro activity of caspofungin (MK-0991) against Candida albicans clinical isolates displaying different mechanisms of azole resistance
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872)
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Echinocandins and pneumocandins--a new antifungal class with a novel mode of action
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Caspofungin acetate: an antifungal agent
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Treatment of murine Candida krusei or Candida glabrata infection with L-743,872
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Efficacy of MK-991 (L-743,872), a semisynthetic pneumocandin, in murine models of Pneumocystis carinii
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900024-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Identifiers
DOI
10.1016/S0733-8635(03)00024-X
1 reference
stated in
Europe PubMed Central
PubMed publication ID
12956208
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12956208%20AND%20SRC:MED&resulttype=core&format=json
retrieved
7 November 2019
PubMed publication ID
12956208
1 reference
stated in
Europe PubMed Central
PubMed publication ID
12956208
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12956208%20AND%20SRC:MED&resulttype=core&format=json
retrieved
7 November 2019
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit